Please try another search
K Pharma,Inc. engages in the research, development, manufacture, and sale of regenerative medicines and pharmaceutical products in Japan. It develops regenerative medicine products using disease-specific induced pluripotent stem (iPS) cell technology for spinal cord injuries and cerebral infarctions. The company was incorporated in 2016 and is based in Minato, Japan.
Name | Age | Since | Title |
---|---|---|---|
Akiko Isohata | 48 | 2022 | Outside Auditor |
Jun Nakanishi | - | 2020 | Scientific Advisor |
Yasutaka Nishida | 47 | 2019 | Outside Auditor |
Hideyuki Okano | 65 | 2019 | CSO & Director |
Kentaro Yoshimatsu | - | 2018 | Scientific Advisor |
Masato Matsumoto | 49 | 2021 | CFO, MD & Director |
Hiroaki Fukushima | 64 | 2016 | President & Representative Director |
Keiko Hatta | 65 | 2022 | Independent Outside Director |
Masaya Nakamura | 63 | 2019 | CTO & Director |
Masato Yano | - | 2019 | Scientific Advisor |
Shunsuke Toyokawa | 66 | 2022 | Full-time Outside Auditor |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review